DEFENDOR: A Multicenter Prospective Observational Post-registration stuDy of Extimia® (INN: empEgfilrastim) to Evaluate Efficacy and saFEty in patieNts With soliD tumORs
This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with solid tumours receiving myelosuppressive therapy
Patients With Solid Tumours Who Receive Myelosupressive Therapy
DRUG: Empegfilgrastim
Relative dose-intensity (RDI) of the myelosupressive therapy course, 12 months
The incidence of febrile neutropenia with empegfilgrastim supportive therapy compared with historical control, 18 months|The incidence of neutropenia leading to a dose reduction of cytostatic drugs and / or an increase of the interval between cycles when using empegfilgrastim supportive therapy compared with historical controls, 18 months|RDI of chemotherapy courses performed in relation to nosology, 18 months|RDI of chemotherapy courses performed in relation to treatment regimen, 18 months|Any grade adverse events frequency, 18 months|Grade 3-4 adverse events frequency, 18 months|Serious adverse events frequency, 18 months|Frequency of study withdrawal due to adverse events, 18 months|The incidence of severe infections (grade 3-4), 18 months|Frequency of antibiotic prescription, 18 months
This study was designed to evaluate the efficacy and safety of Extimia® (INN - empegfilgrastim) in reducing the frequency, duration of neutropenia, the incidence of febrile neutropenia and infections caused by febrile neutropenia in patients with solid tumours receiving myelosuppressive therapy